As of today (2021-12-08), Biomarin Pharmaceutical's share price is $86.12.
Biomarin Pharmaceutical's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2021 was $0.89. Hence, Biomarin Pharmaceutical's Price-to-Free-Cash-Flow Ratio for today is 96.44.
The historical rank and industry rank for Biomarin Pharmaceutical's Price-to-Free-Cash-Flow or its related term are showing as below:
NAS:BMRN'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 82.58 Med: 98.07 Max: 168.58
Current: 96.44
82.58
-
168.58
During the past 13 years, Biomarin Pharmaceutical's highest Price-to-Free-Cash-Flow Ratio was 168.58. The lowest was 82.58. And the median was 98.07.
NAS:BMRN's Price-to-Free-Cash-Flow is ranked lower than
78% of the 213
Companies
in the Biotechnology industry.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 38.90% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 36.60% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was -2.40% per year.
During the past 13 years, Biomarin Pharmaceutical's highest 3-Year average Free Cash Flow per Share Growth Rate was 71.50% per year. The lowest was -131.90% per year. And the median was 3.70% per year.
Biomarin Pharmaceutical Price-to-Free-Cash-Flow Historical Data
The historical data trend for Biomarin Pharmaceutical's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Biomarin Pharmaceutical Annual Data
Trend
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Price-to-Free-Cash-Flow
-
-
-
-
-
Biomarin Pharmaceutical Quarterly Data
Dec16
Mar17
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Price-to-Free-Cash-Flow
-
-
160.32
103.27
86.55
Competitive Comparison
For the Biotechnology subindustry, Biomarin Pharmaceutical's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomarin Pharmaceutical Price-to-Free-Cash-Flow Distribution
For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Biomarin Pharmaceutical's Price-to-Free-Cash-Flow falls into.
Biomarin Pharmaceutical's Share Price of today is $86.12.
Biomarin Pharmaceutical's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.89.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Biomarin Pharmaceutical Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
1.88(2.23%) Volume: 1,227,083 2:08AM EST
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:BMRN has been successfully added to your 
